Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Intangibles (2018 - 2025)

Collegium Pharmaceutical (COLL) has 6 years of Intangibles data on record, last reported at $835.9 million in Q1 2025.

  • For Q1 2025, Intangibles rose 115.9% year-over-year to $835.9 million; the TTM value through Mar 2025 reached $835.9 million, up 115.9%, while the annual FY2024 figure was $891.4 million, 111.38% up from the prior year.
  • Intangibles reached $835.9 million in Q1 2025 per COLL's latest filing, down from $891.4 million in the prior quarter.
  • Across five years, Intangibles topped out at $966.2 million in Q1 2022 and bottomed at $268.7 million in Q4 2021.
  • Average Intangibles over 5 years is $664.7 million, with a median of $609.7 million recorded in 2022.
  • Peak YoY movement for Intangibles: fell 25.69% in 2023, then skyrocketed 115.9% in 2025.
  • A 5-year view of Intangibles shows it stood at $268.7 million in 2021, then surged by 111.17% to $567.5 million in 2022, then dropped by 25.69% to $421.7 million in 2023, then surged by 111.38% to $891.4 million in 2024, then decreased by 6.22% to $835.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Intangibles were $835.9 million in Q1 2025, $891.4 million in Q4 2024, and $387.2 million in Q1 2024.